- Home
- MXL vs TRVI Comparison
MXL vs TRVI Comparison
Compare MXL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXL
- TRVI
- Stock Information
- Founded
- MXL 2003
- TRVI 2011
- Country
- MXL United States
- TRVI United States
- Employees
- MXL N/A
- TRVI N/A
- Industry
- MXL Semiconductors
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MXL Technology
- TRVI Health Care
- Exchange
- MXL Nasdaq
- TRVI Nasdaq
- Market Cap
- MXL 1.2B
- TRVI 1.1B
- IPO Year
- MXL 2010
- TRVI 2019
- Fundamental
- Price
- MXL $16.95
- TRVI $10.37
- Analyst Decision
- MXL Buy
- TRVI Strong Buy
- Analyst Count
- MXL 8
- TRVI 9
- Target Price
- MXL $20.93
- TRVI $20.72
- AVG Volume (30 Days)
- MXL 1.1M
- TRVI 1.7M
- Earning Date
- MXL 10-23-2025
- TRVI 11-05-2025
- Dividend Yield
- MXL N/A
- TRVI N/A
- EPS Growth
- MXL N/A
- TRVI N/A
- EPS
- MXL N/A
- TRVI N/A
- Revenue
- MXL $378,015,000.00
- TRVI N/A
- Revenue This Year
- MXL $28.85
- TRVI N/A
- Revenue Next Year
- MXL $17.69
- TRVI N/A
- P/E Ratio
- MXL N/A
- TRVI N/A
- Revenue Growth
- MXL N/A
- TRVI N/A
- 52 Week Low
- MXL $8.35
- TRVI $2.36
- 52 Week High
- MXL $25.73
- TRVI $11.11
- Technical
- Relative Strength Index (RSI)
- MXL 55.09
- TRVI 68.47
- Support Level
- MXL $14.36
- TRVI $9.29
- Resistance Level
- MXL $17.80
- TRVI $11.11
- Average True Range (ATR)
- MXL 0.98
- TRVI 0.56
- MACD
- MXL 0.12
- TRVI 0.06
- Stochastic Oscillator
- MXL 75.07
- TRVI 75.73
About MXL MaxLinear Inc.
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.